{"id":826890,"date":"2025-03-18T08:39:17","date_gmt":"2025-03-18T12:39:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/"},"modified":"2025-03-18T08:39:17","modified_gmt":"2025-03-18T12:39:17","slug":"cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/","title":{"rendered":"CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BERKELEY HEIGHTS, N.J., March  18, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zGMcgxKXCTzbp2VFtGHcMjrdmUlUJRu1LbLBSZsNCG8fCtysQgniP2fR497yb-btiFGZdqmdyoTY-f1YiFefFU97GLZY7b3KAwf8VJYzeBs=\" rel=\"nofollow\" target=\"_blank\">CorMedix Inc.<\/a> (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Tuesday, March 25, 2025, and will host a corporate update conference call at 8:30am Eastern Time.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"3\" style=\"vertical-align: bottom\">\n            <strong><br \/>\n              <em><br \/>\n                <u>Tuesday, March 25<\/u><br \/>\n              <\/em><br \/>\n            <\/strong><br \/>\n            <sup><br \/>\n              <strong><br \/>\n                <em><br \/>\n                  <u>th<\/u><br \/>\n                <\/em><br \/>\n              <\/strong><br \/>\n            <\/sup><br \/>\n            <strong><br \/>\n              <em><br \/>\n                <u> @ 8:30am ET<\/u><br \/>\n              <\/em><br \/>\n            <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:15%;width:15%;min-width:15%;vertical-align: bottom\">Domestic:<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:84%;width:84%;min-width:84%;vertical-align: bottom\">1-844-481-2557<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">International:<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">1-412-317-0561<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">Conference ID:<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">10197392<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">Webcast:<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\n            <a href=\"https:\/\/event.choruscall.com\/mediaframe\/webcast.html?webcastid=WOjqI4SC\" rel=\"nofollow\" target=\"_blank\">Webcast Link<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>About CorMedix<\/strong>\n      <\/p>\n<p>CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath<sup>\u00ae<\/sup>\u00a0(taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas. For more information visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_8IV3hoUzGbW9ksYfIkGSeSi98JJZn-1McCk8Bc7LfDW4XfRYfpI4UyFH992YIrdVsCSEMSvTbFn7pmR-elNkctIgT1tIJcMH_DYszWO8Eg=\" rel=\"nofollow\" target=\"_blank\">www.cormedix.com<\/a>.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Dan Ferry<br \/>Managing Director<br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DKrBqCZNVpbsV68hTptSRQOm_v5smw2G-cE7J0dLOu4C_8OvgRMhGpEkLBflpDBPk4Ukjxu6Y6FgKmICo0cSjwcl5k_mz3W9KNBiGnph1rDdmtgs8f1AQNNsVXUTUNl9\" rel=\"nofollow\" target=\"_blank\">daniel@lifesciadvisors.com<\/a><br \/>(617) 430-7576<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk1NSM2ODEwNTg3IzUwMDA2NTY3OA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTE3YWMzNWUtNGI4ZS00ZDFhLWI3Y2YtZDMxZmQ1OGNkYmFkLTUwMDA2NTY3OC0yMDI1LTAzLTE4LWVu\/tiny\/CorMedix-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) &#8212; CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Tuesday, March 25, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, March 25 th @ 8:30am ET Domestic: \u00a0 1-844-481-2557 International: \u00a0 1-412-317-0561 Conference ID: \u00a0 10197392 Webcast: \u00a0 Webcast Link \u00a0 \u00a0 \u00a0 About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-826890","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) &#8212; CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Tuesday, March 25, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, March 25 th @ 8:30am ET Domestic: \u00a0 1-844-481-2557 International: \u00a0 1-412-317-0561 Conference ID: \u00a0 10197392 Webcast: \u00a0 Webcast Link \u00a0 \u00a0 \u00a0 About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company &hellip; Continue reading &quot;CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-18T12:39:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk1NSM2ODEwNTg3IzUwMDA2NTY3OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025\",\"datePublished\":\"2025-03-18T12:39:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\\\/\"},\"wordCount\":214,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTk1NSM2ODEwNTg3IzUwMDA2NTY3OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\\\/\",\"name\":\"CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTk1NSM2ODEwNTg3IzUwMDA2NTY3OA==\",\"datePublished\":\"2025-03-18T12:39:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTk1NSM2ODEwNTg3IzUwMDA2NTY3OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTk1NSM2ODEwNTg3IzUwMDA2NTY3OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/","og_locale":"en_US","og_type":"article","og_title":"CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025 - Market Newsdesk","og_description":"BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) &#8212; CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Tuesday, March 25, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, March 25 th @ 8:30am ET Domestic: \u00a0 1-844-481-2557 International: \u00a0 1-412-317-0561 Conference ID: \u00a0 10197392 Webcast: \u00a0 Webcast Link \u00a0 \u00a0 \u00a0 About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company &hellip; Continue reading \"CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-18T12:39:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk1NSM2ODEwNTg3IzUwMDA2NTY3OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025","datePublished":"2025-03-18T12:39:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/"},"wordCount":214,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk1NSM2ODEwNTg3IzUwMDA2NTY3OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/","name":"CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk1NSM2ODEwNTg3IzUwMDA2NTY3OA==","datePublished":"2025-03-18T12:39:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk1NSM2ODEwNTg3IzUwMDA2NTY3OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk1NSM2ODEwNTg3IzUwMDA2NTY3OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-25-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826890","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=826890"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826890\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=826890"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=826890"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=826890"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}